244 related articles for article (PubMed ID: 17522246)
1. FDA drug approval summary: panitumumab (Vectibix).
Giusti RM; Shastri KA; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 May; 12(5):577-83. PubMed ID: 17522246
[TBL] [Abstract][Full Text] [Related]
2. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Giusti RM; Shastri K; Pilaro AM; Fuchs C; Cordoba-Rodriguez R; Koti K; Rothmann M; Men AY; Zhao H; Hughes M; Keegan P; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Mar; 14(5):1296-302. PubMed ID: 18316547
[TBL] [Abstract][Full Text] [Related]
3. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
Van Cutsem E; Peeters M; Siena S; Humblet Y; Hendlisz A; Neyns B; Canon JL; Van Laethem JL; Maurel J; Richardson G; Wolf M; Amado RG
J Clin Oncol; 2007 May; 25(13):1658-64. PubMed ID: 17470858
[TBL] [Abstract][Full Text] [Related]
4. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
Giusti RM; Cohen MH; Keegan P; Pazdur R
Oncologist; 2009 Mar; 14(3):284-90. PubMed ID: 19282350
[TBL] [Abstract][Full Text] [Related]
5. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
Hecht JR; Patnaik A; Berlin J; Venook A; Malik I; Tchekmedyian S; Navale L; Amado RG; Meropol NJ
Cancer; 2007 Sep; 110(5):980-8. PubMed ID: 17671985
[TBL] [Abstract][Full Text] [Related]
6. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
[TBL] [Abstract][Full Text] [Related]
7. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer.
Hecht JR; Mitchell E; Neubauer MA; Burris HA; Swanson P; Lopez T; Buchanan G; Reiner M; Gansert J; Berlin J
Clin Cancer Res; 2010 Apr; 16(7):2205-13. PubMed ID: 20332321
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
9. [Panitumumab-treatment of metastatic colorectal cancer].
Pikó B
Magy Onkol; 2009 Jun; 53(2):135-42. PubMed ID: 19581179
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on panitumumab in metastatic colorectal cancer.
Keating GM
BioDrugs; 2010 Aug; 24(4):275-8. PubMed ID: 20623992
[TBL] [Abstract][Full Text] [Related]
11. Panitumumab: in the treatment of metastatic colorectal cancer.
Hoy SM; Wagstaff AJ
Drugs; 2006; 66(15):2005-14; discussion 2015-6. PubMed ID: 17100412
[TBL] [Abstract][Full Text] [Related]
12. [Panitumumab].
Musch A
Med Monatsschr Pharm; 2008 Apr; 31(4):122-6. PubMed ID: 18497243
[TBL] [Abstract][Full Text] [Related]
13. Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.
Wu M; Rivkin A; Pham T
Clin Ther; 2008 Jan; 30(1):14-30. PubMed ID: 18343240
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.
Muro K; Yoshino T; Doi T; Shirao K; Takiuchi H; Hamamoto Y; Watanabe H; Yang BB; Asahi D
Jpn J Clin Oncol; 2009 May; 39(5):321-6. PubMed ID: 19287023
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.
Saif MW; Kaley K; Chu E; Copur MS
Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847
[TBL] [Abstract][Full Text] [Related]
16. Panitumumab: a review of its use in metastatic colorectal cancer.
Keating GM
Drugs; 2010 May; 70(8):1059-78. PubMed ID: 20481659
[TBL] [Abstract][Full Text] [Related]
17. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Mar; 12(3):356-61. PubMed ID: 17405901
[TBL] [Abstract][Full Text] [Related]
18. A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.
Wang J; Zhao Z; Barber B; Sherrill B; Peeters M; Wiezorek J
Br J Cancer; 2011 Jun; 104(12):1848-53. PubMed ID: 21610704
[TBL] [Abstract][Full Text] [Related]
19. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
[TBL] [Abstract][Full Text] [Related]
20. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
Peeters M; Siena S; Van Cutsem E; Sobrero A; Hendlisz A; Cascinu S; Kalofonos H; Devercelli G; Wolf M; Amado RG
Cancer; 2009 Apr; 115(7):1544-54. PubMed ID: 19189371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
